Vivus is about to have its moment of truth, after a three-month delay helped competitor Arena slide into an early lead to the market. Will the FDA shine favorably on Vivus and give Qnexa a relatively clean approval, or will the drug be a non-starter because of overly restrictive labeling? Watch and find out what it all means for investors.
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.